Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyUrologic OncologyDiseaseNeuroendocrine CarcinomaProstate CancerSubgroupATM-MutationBRCA mutationcastration resistantDNA Repair Defecthormone sensitiveICD10C61C80.9MeSHCarcinoma, NeuroendocrineProstatic DiseasesProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantSequenceARASENS: DOCE75/PRED5/DARO600/GOSE10.8, Prostate Ca (HS), A (PID2040) -|- B (PID2041) -|- C (PID2081)DGRL240, Prostate Ca, C1 (PID1524) -|- DGRL80, C2+ (PID1525)DOCE75/PRED5/GOSE10.8, Prostate Ca (HS), A (PID641) -|- B (PID664) -|- C (PID2082)HERO: RELU(360/120), Prostate Ca, C1 (PID2250) -|- RELU120, C2+ (PID2247).PEACE-1: DOCE75/PRED5/ABIR1000/GOSE10.8, Prostate Ca (HS), A (PID2305) -|- B (PID2306) -|- C (PID2307).ChemotherapyChemo-substanceAbirateroneApalutamideBuserelinCabazitaxelCarboplatinCisplatinDarolutamideDegarelixDexamethasoneDocetaxelEnzalutamideEtoposideGoserelinLeuprorelinMitoxantroneNiraparibOlaparibPrednisoloneRelugolixRucaparibTalazoparibTriptorelinChemo-substanceAbirateroneApalutamideBuserelinCabazitaxelCarboplatinCisplatinDarolutamideDegarelixDexamethasoneDocetaxelEnzalutamideEtoposideGoserelinLeuprorelinMitoxantroneNiraparibOlaparibPrednisoloneRelugolixRucaparibTalazoparibTriptorelinChemo-substanceAbirateroneApalutamideBuserelinCabazitaxelCarboplatinCisplatinDarolutamideDegarelixDexamethasoneDocetaxelEnzalutamideEtoposideGoserelinLeuprorelinMitoxantroneNiraparibOlaparibPrednisoloneRelugolixRucaparibTalazoparibTriptorelinChemo-substanceAbirateroneApalutamideBuserelinCabazitaxelCarboplatinCisplatinDarolutamideDegarelixDexamethasoneDocetaxelEnzalutamideEtoposideGoserelinLeuprorelinMitoxantroneNiraparibOlaparibPrednisoloneRelugolixRucaparibTalazoparibTriptorelinNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances12357Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentioncurative or palliativedisease controlpalliativeRisksAllergic ReactionAlopeciaAnemia Hb below 8g/dlArthalgiaAstheniaBone PainCardiotoxicityConstipationDepressionDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaFractureGynecomastiaHeadacheHeart FailureHematuriaHepatotoxicityHyperglycemiaHyperhidrosisHyperkalemiaHypertensionHypokalemiaHypotensionHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesInfectionsLeukopeniaLibido ReductionMuscle WeaknessNauseaNeuropathyNeutropeniaOral MucositisOsteopeniaPainParesthesiaPneumoniaRashRenal FailureSpinal Cord CompressionThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorAgarwal NApostolidis LBeer TBolton EMChi KChi KNClarke NWCorn PG Davis IDde Bono JDe Bono Jde Bono JSEisenberger MFizazi KHellmann MDKellokumpu-Lehtinen PKlotz LOudard SRomero-Laorden NRyan CScher HShore NDSmith MRSternberg CNSweeney JCTannock ITannock IFDiseaseFortgeschrittenes hormonsensitives Prostatakarzinomfortgeschrittenes oder metastasiertes Prostata-Ca, kastrationsresistent, ECOG 0-2Fortgeschrittenes Prostatakarzinomkastrationsresistentes Prostatakarzinom, Progress nach Docetaxel, Testosteron < 50 ng/dl, ECOG 0-2metastasiertes, hormonresistentes Prostata-Ca, Serumtestosteron < 50 ng/dl, Karnofsky > 60metastasiertes, hormonsensitives Prostata-Ca, Serumtestosteron < 50 ng/dl, ECOG 0-2metastasiertes, hormonsensitives Prostata KarzinomMetastasiertes, hormonsensitives Prostata KarzinomMetastasiertes, hormonsensitives ProstatakarzinomMetastasiertes, kastrationsresistentes Prostata-Ca, Progress unter Abirateron/Prednisolon, Serumtestosteron < 50 ng/dl, ECOG 0-1metastasiertes, kastrationsresistentes Prostata-Ca, Serumtestosteron < 50 ng/dl, ECOG 0-1metastasiertes, kastrationsresistentes Prostata-Ca, symptomatisch, ECOG 0-3metastasiertes, kastrationsresistentes Prostata-Ca mit BRCA1, BRCA2, oder ATM Mutation, Progress nach Androgenrezeptor-Antagonisten der 2. GenerationMetastasiertes, kastrationsresistentes Prostatakarzinom, asymptomatisch oder wenig Symptome, ECOG 0-1metastasiertes, kastrationsresistentes Prostatakarzinom, Progress nach Docetaxel, Testosteron < 50 ng/dl, ECOG 0-2metastasiertes, kastrationsresistentes Proststa Karzinom nach Docetaxel Therapie, ECOG 0-2Metastasiertes hormonsensitives Prostatakarzinom, ECOG 0-1Metastasiertes hormonsensitives Prostatakarzinom, ECOG 0-2, mindestens 2 von 3 Kriterien positiv: Gleason Score gleich oder höher 8; 3 oder mehr Knochenmetastasen; viszerale Metastasen.Metastasiertes kastrationsresistentes Prostata-Ca, ErstlinieMetastasiertes kastrationsresistentes Prostata-Ca, Erstlinie, HRR+Metastasiertes kastrationsresistentes Prostata-Ca, progredient nach Therapie mit z.B. Enzalutamid oder AbirateronMetastasiertes kastrationsresistentes Prostatakarzinom, ECOG 0-2metastasiertes kastrationsresistentes Prostatakarzinom, Erstlinie, ECOG 0-2neudiagnostiziertes Prostatakarzinom, metastasiert, hormonsensitiv, ECOG 0-2Neuroendokrines Prostatakarzinom, Erst- und Zweitlinienicht metastasiertes, kastrationsresistentes Hochrisiko Prostata-Canicht metastasiertes, kastrationsresistentes Prostata-Ca, ECOG 0-1nicht metastasiertes, kastrationsresistentes Prostata-Ca, PSA-Verdopplungszeit weniger als 10 Monate, ECOG 0-1Prostatakarzinom, alle Stadien, ECOG 0-2Originassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, ARASENS trialCarolina Urologic Research Center, Myrtle Beach, SC, HERO trialDepartment of Medical Oncology, University Hospital HeidelbergDepartment of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, TAX 327 InvestigatorsDepartment of Medicine and the Department of Biostatics and Computational Biology, Dana Farber Cancer Institute, BostonDepartment of Oncology, Tampere University Hospital, Tampere, Finland, PROSTY study groupDepartment of Urology, St James's Hospital, Dublin, IrelandDepartment of Urology, St James Hospital, Dublin, IrelandEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, USA, PROSPER trialGenitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, COU-AA-302 InvestigatorsGeorge Pompidou European Hosptial, Paris, FIRSTANAGustave Roussy, University of Paris Sud, Villejuif, France, LATITUDE trialGustave Roussy Institute, Paris-Saclay University, Villejuif, France, TRITON3 trialHuntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA, TALAPRO-2 trialInstitute of Cancer Research and Royal Marsden Hospital, Sutton, COU-AA-301 InvestigatorsInstitute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom, PROfound trialInstitut Gustave Roussy, Universite Paris-Sud, Villejuif, France, ARAMIS trialInstitut Gustave Roussy, University of Paris-Saclay, Villejuif, France, PEACE-1Massachusetts General Hospital Cancer Center, BostonMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, ARASENS trialMemorial Sloan-Kettering Cancer Center, New York, AFFIRM trialMonash University, Australia, ENZAMET TRIALOHSU Knight Cancer Institute, Oregon Health and Science University, PREVAIL trialPrincess Margaret Hospital, Toronto, CanadaRoyal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK, TROPICSpanish National Cancer Research Centre (CNIO), Madrid, Spain, SWITCH trialThe Johns Hopkins University, Baltimore, PROSELICAUniversity of British Columbia, CancerdVancouver Center, Vancouver, Canada, MAGNITUDE trialUniversity of Manchester, Manchester, United Kingdom, PROpel trialUniversity of Paris Sud, Villejuif, France, LATITUDE StudieUniversity of Texas MD Anderson Cancer Center, Houston, USAUniversity of Toronto, CanadaVancouver Prostate Centre, Vancouver, Canada, TITANProtocols in Revision 44 protocols foundProtocols under revision.Abiraterone 1000 / Dexamethasone 0.5, Prostate Cancer Castration Resistant (PID2311 V1.0)Abiraterone 1000 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer, First Line (PID1002 V1.1)Abiraterone 1000 / Prednisolone 5, Prostate Cancer Hormone Sensitive (PID1504 V1.1)Abiraterone 1000 / Prednisolone 5, Prostate Cancer, First Line (PID919 V1.1)Abiraterone 1000 / Prednisolone 5, Prostate Cancer, Second Line (PID920 V1.1)Apalutamide 240, Prostate Cancer hormone sensitive (PID1503 V1.0)Apalutamide 240, Prostate Cancer Castration Resistant (PID1232 V1.1)Buserelin 9.45, Prostate Cancer (PID1523 V2.0)Cabazitaxel 20 / Prednisolone 10, Prostate Cancer, First Line (PID1129 V1.1)Cabazitaxel 20 / Prednisolone 10, Prostate Cancer, Second Line (PID1134 V1.1)Cabazitaxel 25 / Carboplatin 4 / Prednisolone 5 Prostate Cancer (PID2310 V1.0)Cabazitaxel 25 / Prednisolone 10, Prostate Cancer, First Line (PID1104 V1.1)Cabazitaxel 25 / Prednisolone 10, Prostate Cancer, Second Line (PID645 V1.1)Cisplatin 25 / Etoposide 100, Neuroendocrine Prostate Cancer (PID1283 V1.1)Darolutamide 600, Prostate Cancer Castration Resistant (PID1642 V1.0)Degarelix 240, Prostate Cancer, Cycle 1 (PID1524 V1.0)Degarelix 80, Prostate Cancer, Cycle 2+ (PID1525 V1.0)Docetaxel 30 / Prednisolone 5, Prostate Cancer (PID1391 V1.1)Docetaxel 50 / Prednisolone 10, Prostate Cancer (PID941 V1.1)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8 -Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part C (PID2307 V1.0)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part A (PID2305 V1.0)Docetaxel 75 / Prednisolone 5 / Abiraterone 1000 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part B (PID2306 V1.0)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8 - Darolutamide 600 / Goserelin 10.8, Prostate Cancer hormone sensitive, part C (PID2081 V1.0)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8, Prostate Cancer Hormone Sensitive, part A (PID2040 V1.1)Docetaxel 75 / Prednisolone 5 / Darolutamide 600 / Goserelin 10.8, Prostate Cancer hormone sensitive, part B (PID2041 V1.1)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8 - Goserelin 10.8, Prostate Cancer hormone sensitive, part C (PID2082 V1.0)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part A (PID641 V2.0)Docetaxel 75 / Prednisolone 5 / Goserelin 10.8, Prostate Cancer hormone sensitive, Part B (PID664 V2.0)Docetaxel 75 / Prednisolone 5, Prostate Cancer (PID921 V1.1)Enzalutamide 160 / Goserelin 10.8, Prostate Cancer Hormone Sensitive, First Line (PID1360 V2.0)Enzalutamide 160, Prostate Cancer Castration Resistant (PID1557 V1.0)Enzalutamide 160, Prostate Cancer castration-resistant, first-line (PID918 V1.0)Enzalutamide 160, Prostate Cancer castration-resistant, second-line (PID917 V1.0)Goserelin 10.8, Prostate Cancer (PID1520 V1.0)Leuprorelin 11.25, Prostate Cancer (PID1521 V1.0)Mitoxantrone 12 / Prednisolone 5, Prostate Cancer castration resistant (PID2309 V1.0)Niraparib 200 / Abiraterone 1000 / Prednisolone 10, Prostate Cancer castration-resistant (PID2557 V1.0)Olaparib 300 / Abiraterone 1000 / Prednisolone 5, Prostate Cancer castration resistant (PID2326 V1.0)Olaparib 300, Prostate Cancer Castration Resistant (PID1559 V1.0)Relugolix (360/120), Prostate Cancer, Cycle 1 (PID2250 V1.0)Relugolix 120, Prostate Cancer, Cycle 2+ (PID2247 V1.0)Rucaparib 600, Prostate Cancer Castration Resistant (PID2308 V1.0)Talazoparib 0.5 / Enzalutamide 160, Prostate Cancer castration-resistant (PID2556 V1.0)Triptorelin 11,25, Prostate Cancer (PID1522 V1.0)
